维德思投资 VRTS 深 沪
已收盘 12-24 16:00:00 美东时间
166.56
+1.030
+0.62%
华盛通- 最 高168.58
- 今 开166.15
- 成交量 4.40万股
- 最 低 164.64
- 昨 收 165.53
- 总市值 11.25亿
- 52周最高 214.81
- 市盈率 静 9.86
- 换手率 0.65%
- 52周最低 135.28
- 委 比 52.67%
- 总股本 675.44万
- 历史最高 307.20
- 量 比 0.46
- 振 幅 2.38%
- 历史最低 2.69
- 每 手 1
- 风险率 17.63%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅63.56%！拜玛林制药获Truist Securities升目标价至100美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持拜玛林制药"买入"评级，目标价从80美元升至100美元；HC Wainwright & Co.：维持Savara"买入"评级，目标价从8美元升至10美元
12-24 11:17
Piper Sandler Maintains Overweight on Virtus Inv, Lowers Price Target to $218
Piper Sandler analyst Crispin Love maintains Virtus Inv (NYSE:VRTS) with a Overweight and lowers the price target from $225 to $218.
12-23 18:28
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
12-18 10:54
Virtus Investment Partners Acquires Stake in Crescent Cove
An update from Virtus Investment Partners ( ($VRTS) ) is now available. On Dece...
12-16 22:17
Citigroup, Leidos Holdings And More On CNBC's 'Final Trades'
On CNBC's "Halftime Report," Joseph M. Terranova of Virtus Investment Partners picked Citigroup Inc. to be his "final trade."
12-16 21:36
美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
12-15 15:30
Barclays Maintains Underweight on Virtus Inv, Lowers Price Target to $158
Barclays analyst Benjamin Budish maintains Virtus Inv (NYSE:VRTS) with a Underweight and lowers the price target from $175 to $158.
12-13 04:34
Virtus Investment declares $2.40 dividend
Virtus Investment (VRTS) declared $2.40/share quarterly dividend, in line with previous. Forward yield 5.84% Payable Feb. 11; for shareholders of record Jan. 31; ex-div Jan. 30. See VRTS Dividend Scor...
12-11 20:59
Virtus Investment estimates decrease in November-end AUM
Virtus Investment Partners (VRTS) on Wednesday announced preliminary assets under management of $164.2B as of November 30, compared to $166.2B at the end of October. The decrease reflects market perfo...
12-10 20:19
Monolithic Power, Ascendis Pharma And More: CNBC's 'Final Trades'
Amy Raskin, CIO at Chevy Chase Trust, named Ascendis Pharma (ASND) as her final trade on CNBC's Halftime Report. FDA extended review for TransCon CNP.
12-09 21:16
